2021 social responsibility report summary
Introduction to the report
This report is Sichuan Kelun Pharmaceutical Co.Ltd(002422) (hereinafter referred to as “the company”, “Kelun”, “Kelun”)
The 10th social responsibility report issued by the pharmaceutical industry. This report reviews the actual operation of the company in 2021
At the same time of its own development, it actively performs its social responsibility.
Preparation basis
The report is based on the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 1 – listed companies on the main board
Standardized operation of the company, as well as the requirements for the disclosure of social responsibility reports of listed companies and China stock exchange
Corporate social responsibility report preparation guide and other relevant requirements are prepared in combination with the actual situation of the company.
Time range
The report period is moderately extended from January to December 31, 2021.
Release cycle
The report is an annual report, which is issued at the same time as the company’s annual report.
Scope of report
The scope of the report is Sichuan Kelun Pharmaceutical Co.Ltd(002422) and its subordinate enterprises.
Data source
The operating data in the report comes from the audited annual report of the company, and other data comes from within the company
Document and information statistics system. Unless otherwise noted, all data are consolidated data of the company.
Report acquisition
On the information disclosure website designated by Shenzhen Stock Exchange, http://www.cn.info.com.cn And
Sichuan Kelun Pharmaceutical Co.Ltd(002422) website (www.kelun. Com.) The electronic document of this report can be downloaded. If you want to
Information other than this report can be supplemented by reading the company’s annual report or browsing the company’s website.
2021 Social Responsibility Report
2021 Social Responsibility Report
Preface when the dawn of the 21st century shines, Lun is lucky to become the guardian of human life, and
At that time, we have reason to believe that colleagues in scientific and medical circles will join hands to conquer diseases
The perfect combination of technology and ethics is a struggle for people’s health and happiness,
The lofty concept of new human survival and development. Dedicate yourself to social stability and prosperity
Just as her resounding name “Colleen” is the power of one. At the same time, Colleen actively undertakes the investment in shares
Jiedong, employees, customers and consumers, society
It shows the responsibilities of stakeholders such as the profundity of Sichuan Kelun Pharmaceutical Co.Ltd(002422) corporate culture and strives to realize
Connotation. Integration of enterprise economic benefits and social responsibility
We are well aware that Colleen’s development is unified and continues to adhere to enterprise management and environmental protection
Mongolia is concerned and loved by all sectors of society. Pay equal attention to the balance between science and business.
“Science seeks truth, ethics seeks goodness”
Science and technology
And ethics
The perfect combination of is the new human“
Active commitment
Survival and development shareholders employees customers social interests of consumers
Relevant responsibilities
A noble idea.
2021 Social Responsibility Report 3
Overviewchapter 1 Overview
Sichuan Kelun Pharmaceutical Co.Ltd(002422) since its establishment, it has focused on foreign medical aid projects. The company in tumor, bacterial infection
This paper reviews the pharmaceutical manufacturing field, mainly engaged in many disease fields such as high-volume injection, parenteral camp, cardio cerebrovascular and so on
(infusion), small volume injection (water needle), and the development of more than 400 major drugs have been launched,
Sterile powder for injection (including sub packaged powder injection and freeze-drying) has been authorized overseas with a number of innovative patents.
Colleen will be more
Powder injection), tablet, capsule, granule and mouth serve patients with high quality and improve people’s health
The quality of 23 dosage forms such as oral liquid and peritoneal dialysis liquid can improve people’s health and well-being.
Products, as well as antibiotic intermediates, APIs and medical quality are the lifeline of pharmaceutical enterprises
R & D, production and sales of drug packaging materials and other products. The safety of the public. Colleen firmly established
Accumulated Sichuan Kelun Pharmaceutical Co.Ltd(002422) adhere to the “three engine drive, innovate the concept of great quality”, and establish reliable quality control and quality control
The strategy of “super growth of R & D investment” maintains a high R & D volume detection system every year to ensure the survival of all member enterprises
RMB 8.5 billion
Investment intensity: the drugs that have been put into production since 2013 are safe and effective. Meanwhile, Colleen
Over 850 million yuan Sichuan Kelun Pharmaceutical Co.Ltd(002422) independent research and development of the pharmaceutical industry has also invested in green and environmental protection innovation
Stand bag with multiple patented technologies ® In protecting the people’s one billion yuan, the company holds high the “environmental protection first and sustainable development”
People have the banner of “development” in drug safety, energy conservation and environmental protection, and various innovative methods have been adopted
It has great promotion value and won the advanced “three wastes” treatment technology of national scientific and technological progress
start-up
Award In the rescue work of “5.12” Wenchuan earthquake, strict environmental protection standards were adopted and green recycling was actively practiced
More than 400 items
Vertical bag ® It has played an irreplaceable role in environmental economy, cleaner production, energy conservation and emission reduction
Major drugs are developed as infusion products that can not be broken, which are implemented to the disaster areas, and strive to become the benchmark for the treatment of “three wastes” in the industry
The urgent airdrop saved countless lives. End of target enterprise.
Previously, the company has established a national post doctoral scientific research Sichuan Kelun Pharmaceutical Co.Ltd(002422) adhering to the principle of “science, truth and ethics”
Workstation and academician workstation, which have applied for patent and seek goodness, have established the enterprise tenet of taking efficiency as the core
More than 4000 patents have been applied for, and more than 2000 patents have been granted. The first distribution is mainly government finance and taxation
More than 4000 items were allocated and three times were mainly social charities
13 “national key new products”
No. 1. It has successively undertaken the harmonious development consciousness of the division distribution of 15 “major new drug creation”.
Major technological projects, a national science and technology support plan, after more than 20 years of development, collen now has
One national key R & D plan and one national science and technology project, with more than 70 subsidiaries (branches) at home and abroad, are
It has more than 70 subsidiaries (branches) outside China for more than 20 years
2459 patents authorized
Offer about
365 invention patents
2 Shenzhen China Bicycle Company (Holdings) Limited(000017) 38 utility model patents
365 design patents
Jobs
Nearly 20000 social workers have provided jobs. Adhering to the original intention to social charitable organizations, charitable funds
Through the deep integration with the capital market and the continuous donation of funds from disaster and epidemic areas, collen has made a summary of about 47594647
Industrial upgrading and meta analysis of the strategic resources of the industry.
Effective integration has made Colleen a standard of management and the Fourth Plenary Session of the 18th CPC Central Committee clearly put forward the need to
The modern pharmaceutical industry with satisfactory, civilized and affluent employees will strengthen the legislation of corporate social responsibility, Sichuan Kelun Pharmaceutical Co.Ltd(002422) as the year of 2021
Regiment. In 2021, the operating income of Kelun pharmaceutical exceeded that of responsible pharmaceutical enterprises, and social responsibility management was regarded as the operating income exceeding that of responsible pharmaceutical enterprises
17.2 billion yuan and profits and taxes of more than 2.745 billion yuan. As an important part of enterprise management innovation, it continued to strengthen 17.2 billion yuan
Sichuan Kelun Pharmaceutical Co.Ltd(002422) earnestly practice the awareness of social responsibility of Xi Jinping general secretary and employees, and show an excellent
On “comprehensively promoting rural revitalization, consolidating and expanding the” sustainable, steady and harmonious development “of private enterprises
The clear requirements of “poverty alleviation achievements” and actively undertake the good image of the enterprise.
The responsibility of the company as a member of the society has been for the public over the years. This report systematically summarizes the company in 2021
The donations provided by Yishi, Guangcai and philanthropy are in excess of the tax to protect the rights and interests of shareholders and creditors and the rights of employees
The total amount of assistance has exceeded 100 million yuan, highlighting the benefits of Kelun pharmaceutical, the protection of the rights and interests of suppliers, customers and consumers, the concept of wealth quality and sense of social justice of the industry of 2.745 billion yuan, and the environment
